Showing 861 - 880 results of 152,407 for search '(( 2 a decrease ) OR ( 5 ((((ng decrease) OR (nn decrease))) OR (mean decrease)) ))', query time: 1.65s Refine Results
  1. 861
  2. 862
  3. 863
  4. 864

    PLD2 and mTORC2 are required to convert increases in membrane tension to decreases in actin network assembly. by Alba Diz-Muñoz (236517)

    Published 2016
    “…<p><b>(A)</b> Prediction: Knockdown of the PLD2–mTORC2-based tension circuit should result in a slower decrease of actin nucleation following an increase in membrane tension. …”
  5. 865
  6. 866
  7. 867
  8. 868
  9. 869
  10. 870
  11. 871
  12. 872
  13. 873
  14. 874
  15. 875
  16. 876

    Effect of OKN-007 on the immunoexpression of PDGFR-α in IC3752 pGBM tumor bearing mice. by Patricia Coutinho de Souza (780490)

    Published 2015
    “…OKN-007 (NR); (4) Normal vs. OKN-007 (R); (5) UT vs. OKN-007 (NR); and (6) Normal vs. OKN-007 (NR).…”
  17. 877

    Image2_A Novel Plant Leaf Patch Absorbed With IL-33 Antibody Decreases Venous Neointimal hyperplasia.TIFF by Boao Xie (11621803)

    Published 2021
    “…IL-33 plays a role in venous neointimal hyperplasia both in humans and rats; neutralization of IL-33 by IL-33 antibody can be a therapeutic method to decrease venous neointimal hyperplasia.…”
  18. 878
  19. 879

    Decreased steady-state levels of <i>Rgs8</i> message and protein in BAC-Q72 mice. by Warunee Dansithong (119577)

    Published 2015
    “…<b>(C)</b> SCA2 patient-derived LB cells demonstrate decreased <i>RGS8</i> transcripts. …”
  20. 880

    MCP-1-deficiency decreased CD11c-expressing cells via impairing the production of ROS and decreased activation of PLCγ2, Akt, and ERK upon M-CSF stimulation in BMM. by Woon-Ki Kim (447798)

    Published 2013
    “…<p>BMMs from WT (open bar) and MCP-1-KO mice (oblique-lined bar) were incubated in the presence of M-CSF (30 ng/ml) with U73122 (10 µM), Akt inhibitor IV (0.3 µM), PD098059 (5 µM), DPI (50 nM), NAC (3 mM), or H<sub>2</sub>O<sub>2</sub> (300 µM) for 4 d (A). *, <i>P</i><0.05; ***, <i>P</i><0.001 compared with vehicle-treated WT cells. …”